Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3193-3198

  Dalbagni, Guido ^a   Russo, Paul ^a   Sheinfeld, Joel ^a   Mazumdar, Madhu ^a   Tong, William ^a   Rabbani, Farhang ^a   Donat, Machelle S ^a   Herr, Harry W ^a   Sogani, Pramod ^a   dePalma, Dominique ^a   Bajorin, Dean ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; GEMCITABINE; MITOMYCIN; SODIUM CHLORIDE; THIOTEPA; VALRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER IRRITATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HEMATURIA; HUMAN; ILLNESS BEHAVIOR; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SUPERFICIAL CANCER; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0036682430     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.066     Document Type: Article

References (33)

1. Cancer statistics, 2001
2. The lower urinary tract
3. Overview of treatment of superficial bladder cancer
4. Superficial bladder cancer: Progression and recurrence
5. An overview of intravesical therapy for superficial bladder tumors
6. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder
7. Intravesical therapy in superficial bladder cancer
8. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer
9. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional cell carcinoma of the bladder
10. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer
11. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT 1 papillary carcinoma and carcinoma in situ of the bladder
12. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin-Participating clinics
13. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma
14. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma: Swedish-Norwegian Bladder Cancer Study Group
15. BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: Results of a prospective randomized study using modified treatment schemes
16. Carcinoma in situ of the bladder
17. Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression
18. The treated natural history of high risk superficial bladder cancer: 15-Year outcome
19. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up
20. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: The Valrubicin Study Group
21. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
22. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
23. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
24. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
25. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Co-operative Group on Bladder Cancer
26. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
27. Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs
28. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine
29. Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial
30. An overview of the treatment of superficial bladder cancer: Intravesical chemotherapy
31. Thiotepa in the treatment of tumours of the bladder
32. Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma
33. Pharmacokinetics: The dynamics of drug absorption, distribution and elimination